Proposed 'MAPS Act' to Map U.S. Pharmaceutical Supply Chains

The Frame

What this does

This amendment would create new federal requirements for tracking the origin of critical medications and reporting on foreign-sourced drugs used by the military, potentially impacting how the government manages pharmaceutical procurement and supply chain security.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Department of Health and Human Services

The agency is tasked with mapping pharmaceutical supply chains and coordinating with other federal departments.

Department of Defense

The agency must produce biannual reports on its pharmaceutical procurement from the People's Republic of China.

Pharmaceutical manufacturers

Manufacturers may be subject to increased data collection and reporting requirements regarding their supply chains and production locations.

What changed

Last recorded activity June 24, 2026.

What's next

Next step not available in the current record.

Summary

Senate Amendment 6067, known as the 'MAPS Act,' would require the Department of Health and Human Services to map pharmaceutical supply chains for critical drugs and biological products. The bill aims to identify vulnerabilities related to national security and drug shortages, while requiring the Department of Defense to report on its purchases of drugs sourced from the People's Republic of China.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Why It Matters

This amendment would create new federal requirements for tracking the origin of critical medications and reporting on foreign-sourced drugs used by the military, potentially impacting how the government manages pharmaceutical procurement and supply chain security.

Frequently Asked Questions

What is the purpose of the MAPS Act?

The act aims to map pharmaceutical supply chains to identify vulnerabilities that could threaten national security or lead to drug shortages.

What information will the Department of Defense have to report?

The Department of Defense must report every 180 days on any drugs it purchased that contain ingredients from, or were manufactured in, the People's Republic of China.

Will this act expose confidential business information?

The act includes provisions to ensure that information exchanged between agencies remains protected as trade secrets or .

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Related Legislation

hearing_transcript

1964 Senate Hearing on Hospital Construction Legislation

This document is a transcript of a 1964 Senate subcommittee hearing regarding three proposed bills aimed at updating the Public Health Service Act to

hearing_transcript

Senate Hearing on 21st Century Cures Act Health IT Implementation

The Senate Committee on Health, Education, Labor, and Pensions held its first oversight hearing to review the implementation of the 21st Century Cures

congressional_record

Senate Scheduling Update for S. 4784

The Senate has agreed to delay the vote on a cloture motion for S. 4784 until after the confirmation vote for the Schwartz nomination. This procedural

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Increased Focus on Foreign Sourcing

The amendment signals a shift toward mandatory transparency regarding the reliance of the U.S. military on pharmaceutical products sourced from the People's Republic of China.

Department of Defense People's Republic of China

Connected Entities

organizationDepartment of Defense“Agency required to report on drug purchases from China”Map →

personMs. Slotkin“Senator who co-sponsored the amendment”Map →

personMr. Lankford“Senator who co-sponsored the amendment”Map →

personMr. Peters“Senator who submitted the amendment”Map →

organizationDepartment of Health and Human Services“Primary agency responsible for mapping supply chains”Map →

personMr. Kaine“Senator who co-sponsored the amendment”Map →

locationPeople's Republic of China“Country of origin for pharmaceutical supply chain reporting”Map →

personMr. King“Senator who co-sponsored the amendment”Map →

personMr. Cotton“Senator who co-sponsored the amendment”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance85
How much this matters to a regular citizen
Controversy40
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz30
Current news / social attention level